Sandbox:patho: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| (5 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
* Neuroblastic tumors may be grouped according to International Neuroblastoma Pathology Classification (Shimada classification) into two groups: schwannian stroma rich group and a schwannian stroma poor group as illustrated below:<ref name="Stanford">Neuroblastoma, Ganglioneuroblastoma and Ganglioneuroma. Stanford Medicine Surgical Pathology Criteria(2015) http://surgpathcriteria.stanford.edu/srbc/neuroblastoma-ganglioneuroblastoma-ganglioneuroma/ Accessed on October, 5 2015</ref><ref name="pmid11745303">{{cite journal| author=Shimada H, Umehara S, Monobe Y, Hachitanda Y, Nakagawa A, Goto S et al.| title=International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group. | journal=Cancer | year= 2001 | volume= 92 | issue= 9 | pages= 2451-61 | pmid=11745303 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11745303 }} </ref> | |||
<br> | |||
{{Family tree/start}} | {{Family tree/start}} | ||
{{familytree | | | | Y01 | | | | | | | | | | Y01=<div style="width: 20em; padding:0.5em;">''' | {{familytree | | | | Y01 | | | | | | | | | | Y01=<div style="width: 20em; padding:0.5em;">''' Neuroblastic tumors'''</div>}} | ||
{{familytree | | |,|-|^|-|.| | | | | | | | }} | {{familytree | | |,|-|^|-|.| | | | | | | | }} | ||
{{familytree | | X01 | | X02 | | | | | | |X01='''Schwannian stroma rich group'''| X02='''Schwannian stroma poor group'''}} | {{familytree | | X01 | | X02 | | | | | | |X01='''Schwannian stroma rich group'''| X02='''Schwannian stroma poor group'''}} | ||
{{familytree|boxstyle= border-top: 0px;| | A01 | | A03 | | | | | | |A01=<div style="width: 20em; padding:1em;"> | {{familytree|boxstyle= border-top: 0px;| | A01 | | A03 | | | | | | |A01=<div style="width: 20em; padding:1em;"> | ||
''' | '''Undifferentiated neuroblastoma'''<br>'''Poorly differentiated neuroblastoma'''<br>'''Differentiating neuroblastoma'''</div>|A03=<div style="width: 20em; padding:1em;">|A03=<div style="width: 20em; padding:1em;"> | ||
''' | '''Nodular ganglioneuroblastoma'''<br>'''Intermixed ganglioneuroblastoma'''<br>'''Maturing ganglioneuroma'''<br>'''Mature ganglioneuroma''' </div>}} | ||
{{Family tree/end}} | {{Family tree/end}} | ||
<br> | |||
* Based on the degree of the cellular maturity and composition, neuroblastoma may be further classified into three subtypes according to the International Neuroblastoma Pathology Classification which include:<ref name="Stanford">Neuroblastoma, Ganglioneuroblastoma and Ganglioneuroma. Stanford Medicine Surgical Pathology Criteria(2015) http://surgpathcriteria.stanford.edu/srbc/neuroblastoma-ganglioneuroblastoma-ganglioneuroma/ Accessed on October, 5 2015</ref> | |||
:* Undifferentiated neruoblastoma | |||
:* Poorly differentiated neuroblastoma | |||
:* Differentiating neuroblastoma | |||
* The table below summarizes the differnces between the three histological subtypes of neurublastoma: | |||
{| | |||
! style="background: #4479BA; width: 200px; color: #FFFFFF;"|'''Risk Factor''' | |||
! style="background: #4479BA; width: 600px; color: #FFFFFF;"|'''Description''' | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | '''Undifferentiated neruoblastoma'''|| style="padding: 5px 5px; background: #F5F5F5;" | Completely formed by neuroblasts with no maturity of ganglion cells | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | '''Poorly differentiated neuroblastoma'''|| style="padding: 5px 5px; background: #F5F5F5;" |Mostly formed by neuroblasts with less the 5% maturing ganglion cells | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | '''Differentiating neuroblastoma'''|| style="padding: 5px 5px; background: #F5F5F5;" | | |||
Predominantly formed by neuroblasts but with more than 5% mature ganglion cells | |||
|} | |||
Latest revision as of 01:13, 6 October 2015
- Neuroblastic tumors may be grouped according to International Neuroblastoma Pathology Classification (Shimada classification) into two groups: schwannian stroma rich group and a schwannian stroma poor group as illustrated below:[1][2]
Neuroblastic tumors | |||||||||||||||||||||||||||||
| Schwannian stroma rich group | Schwannian stroma poor group | ||||||||||||||||||||||||||||
Undifferentiated neuroblastoma Poorly differentiated neuroblastoma Differentiating neuroblastoma |
Nodular ganglioneuroblastoma Intermixed ganglioneuroblastoma Maturing ganglioneuroma Mature ganglioneuroma | ||||||||||||||||||||||||||||
- Based on the degree of the cellular maturity and composition, neuroblastoma may be further classified into three subtypes according to the International Neuroblastoma Pathology Classification which include:[1]
- Undifferentiated neruoblastoma
- Poorly differentiated neuroblastoma
- Differentiating neuroblastoma
- The table below summarizes the differnces between the three histological subtypes of neurublastoma:
| Risk Factor | Description |
|---|---|
| Undifferentiated neruoblastoma | Completely formed by neuroblasts with no maturity of ganglion cells |
| Poorly differentiated neuroblastoma | Mostly formed by neuroblasts with less the 5% maturing ganglion cells |
| Differentiating neuroblastoma |
Predominantly formed by neuroblasts but with more than 5% mature ganglion cells |
- ↑ 1.0 1.1 Neuroblastoma, Ganglioneuroblastoma and Ganglioneuroma. Stanford Medicine Surgical Pathology Criteria(2015) http://surgpathcriteria.stanford.edu/srbc/neuroblastoma-ganglioneuroblastoma-ganglioneuroma/ Accessed on October, 5 2015
- ↑ Shimada H, Umehara S, Monobe Y, Hachitanda Y, Nakagawa A, Goto S; et al. (2001). "International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group". Cancer. 92 (9): 2451–61. PMID 11745303.